Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JK07 in HFrEF
NCT04210375Phase 1Completed
- Sponsor
- Salubris Biotherapeutics
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Peptides, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing JK07 with Matching Placebo (2 arms). Primary endpoint: Incidence and Severity of Treatment-emergent Adverse Events. Started Sep 2020; status: completed.
02
Drugs
JK07
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04210375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210375.